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Abstract
Introduction: We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal
failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate.
Case presentation: A 68-year old Caucasian man presented with progressive pain in both legs two weeks after
commencing treatment with EVG/COBI/FTC/TDF. He was found to have biochemical evidence of rhabdomyolysis
and acute renal failure.
Conclusion: We emphasize the need for post marketing surveillance of adverse effects of new products.
Pharmacokinetic studies are necessary to investigate the levels of pravastatin in patients taking COBI and fenofibrate
with and without other comorbidities. Meanwhile, we suggest that creatine kinase levels should be monitored and
patients advised to report myalgias when using concomitant EVG/COBI/FTC/TDF and pravastatin/fenofibrate. This
case serves as an important reminder to use estimated glomerular filtration rates rather than serum creatinine levels
when choosing new medications. If potentially nephrotoxic combinations are started in patients with borderline
estimated glomerular filtration rates, it may be prudent to check these filtration rates more frequently than usual. In
patients with reduced estimated glomerular filtration rates, potentially nephrotoxic combinations should be avoided
wherever possible.
Introduction
The novel single tablet regimen of elvitegravir (EVG), cobi-
cistat (COBI), emtricitabine (FTC), and tenofovir disoproxil
fumarate (TDF) is used to treat human immunodeficiency
virus (HIV)-1 infection. Contemporary guidelines do not
advise caution, dose adjustments, or enhanced monitoring
of patients who are taking concomitant pravastatin and
EVG/COBI/FTC/TDF [1]. We describe the case of a 68-
year-old patient who developed rhabdomyolysis and acute
kidney injury (AKI) following the commencement of EVG/
COBI/FTC/TDF. To the best of our knowledge, this is the
first such case reported in the literature.
Case presentation
Our patient, a 68-year old Caucasian man, was first
diagnosed with HIV-1 infection in 1993. After six years
on FTC, zidovudine, and ritonavir-boosted lopinavir he
was switched to EVG/COBI/FTC/TDF owing to the
* Correspondence: ckenyon@itg.be
2Department of Clinical Sciences, Institute of Tropical Medicine,
Kronenburgstraat 43/3, 2000 Antwerp, Belgium
Full list of author information is available at the end of the article
JOURNAL OF MEDICAL
CASE REPORTS
© 2015 Suttels et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Suttels et al. Journal of Medical Case Reports  (2015) 9:190 
DOI 10.1186/s13256-015-0671-z
development of dyslipidemia and a desire for treatment
simplification. He also had hypertension, gout, and im-
paired renal function. His weight was 73kg with a body
mass index of 24.7kg/m2. At the time of the therapy
switch, his serum creatinine level was in the normal
range (1.16mg/dL) and results from a urine analysis
were normal, but his estimated glomerular filtration
rate (eGFR) via both the Modification of Diet in Renal
Disease (MDRD) and the Cockcroft–Gault formulas
was slightly reduced (66.6mL/min per 1.73m2 and
62.9mL/min per 1.73m2, respectively). Other medica-
tions he continued to take were acetyl salicylic acid
80mg, lisinopril 5mg, pravastatin 40mg, fenofibrate
267mg, and allopurinol 100mg (all once daily). Our pa-
tient’s age, comorbidities, polypharmacy, and slightly
impaired renal function were possible risk factors for
altered drug effects and interactions [2].
Two weeks after the switch, our patient developed
progressive pain in both calves and thighs. The following
week he experienced anorexia, nausea, and dark urine,
and presented to our hospital with clinical and biochem-
ical evidence of established rhabdomyolysis and acute
tubular necrosis.
A laboratory investigation on admission revealed the
following: creatine kinase (CK) >20,000U/L, creatinine
11.9mg/dL, urea 248mg/dL, and eGFR 4mL/min per
1.73m2. His electrolytes and thyroid function tests were
normal. A urine analysis showed evidence of acute tubu-
lar necrosis. He tested negative for the rs4363657 single-
nucleotide polymorphism located within SLCO1B1 gene.
This gene encodes the organic anion transporting poly-
peptide 1B1 (OATP1B1) that has been associated with
statin-induced myopathy defined as muscle pain or
weakness with elevated CK levels [3].
All medication was discontinued and intravenous fluid
replacement was initiated. Gradually, the myalgia re-
solved and his renal function recuperated without the
need for dialysis. Antiretroviral therapy was recom-
menced three weeks after admission, first with darunavir,
norvir, lamivudine, and abacavir, adjusted according to
his eGFR. After one week, the darunavir was changed to
lopinavir because of persisting gastrointestinal com-
plaints. On discharge, four weeks after admission, his
serum creatinine was 4.8mg/dL and his eGFR was
12mL/min per 1.73m2. At last evaluation five months
post-discharge, he was asymptomatic and his kidney
function showed further improvement (serum creatinine
of 1.51mg/dL and eGFR of 47mL/min per 1.73m2). His
CD4 lymphocyte count was 810 cells/μL and he had an
undetectable viral load (<20 copies/mL).
Discussion
The nature and timing of our patient’s presentation with
rhabdomyolysis-induced AKI two weeks after switching to
EVG/COBI/FTC/TDF suggests a drug-induced etiology.
His Naranjo Adverse Drug Reaction Probability Score was
6 (indicating a probable adverse drug event) [4]. It is pos-
sible that a number of factors combined to cause the
rhabdomyolysis (Fig. 1). His age and reduced eGFR at
baseline would have predisposed him to nephrotoxicity
from TDF and fenofibrate [5–7]. Besides his chronic HIV
infection and hypertension, it is possible that his chronic
aspirin treatment, albeit in low doses, may have reduced
his baseline renal function [8]. This reduced GFR could
have increased his serum levels of fenofibrate, TDF, and,
to a lesser extent, pravastatin [2, 6].
COBI is a novel potent CYP3A4 inhibitor, used to boost
the levels of EVG in the co-formulation EVG/COBI/FTC/
TDF [9]. It also inhibits the secretion of creatinine by the
proximal tubule, leading to a slight (<10%) increase in
serum creatinine and a decrease of eGFR. There is no
evidence of a decline in actual GFR and the decline in
eGFR is fully and promptly reversible upon discontinu-
ation [9, 10]. COBI has not been studied in patients with
an eGFR under 70mL/min per 1.73m2. COBI has a
number of other off-target effects. It inhibits CYP2A6, p-
glycoprotein (P-gp), and OATP1B1 [11]. Although both
pravastatin and rosuvastatin undergo minimal CYP450
metabolism, a pharmacokinetic study showed that COBI
increased the maximum serum concentration of rosuvas-
tatin by 89%. This was thought to be due to COBI-induced
inhibition of intestinal efflux by breast cancer resistance
protein (BCRP) or hepatic uptake by OATPs [12].
Although no pharmacokinetic studies have been per-
formed on the interaction between COBI and prava-
statin, COBI would be expected to increase the serum
levels of pravastatin by a number of mechanisms: inhi-
bition of BCRP intestinal and biliary efflux pumps; in-
hibition of the P-gp intestinal, biliary, and renal efflux
pumps; and inhibition of OATP1B1-mediated entry into
hepatocytes [9, 13]. Pravastatin levels inside skeletal
muscle cells may also be increased by COBI-induced in-
hibition of P-gp efflux from these cells [14]. Statin-
induced rhabdomyolysis is thought to result from a
number of factors. Drug interactions, particularly those
leading to increased levels of statins, have been found to
play a prominent role in a number of studies [15–17]. The
predicted increase in pravastatin levels in serum and
muscle cells in our patient may thus have been sufficient
to trigger rhabdomyolysis, which would have caused a
further decline in eGFR leading to self-reinforcing in-
creases in TDF and pravastatin/fenofibrate. The observed
enhanced risk of rhabdomyolysis when pravastatin is used
simultaneously with a high dose fenofibrate may also be
mediated by fibrate inhibition of statin excretion and
hence higher serum statin levels [18]. It is also possible
that EVG played a role. There have been six case reports
of raltegravir (another integrase inhibitor) linked to
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rhabdomyolysis. Pravastatin was used concomitantly in one
of these cases [19]. Of potential relevance to our case, this
association has only been detected during post marketing
surveillance. As a result of these cases, the US Food and
Drug Administration now recommends caution in using
raltegravir in patients with increased risk for muscle dam-
age [20]. Finally, there have been reports of acute tubular
necrosis after adding TDF to lisinopril therapy [21].
Conclusion
Two large trials reporting the efficacy of EVG/COBI/FTC/
TDF were industry sponsored [22, 23]. A Cochrane review
found that industry-sponsored clinical trials are signifi-
cantly more likely than non-commercially funded studies
to report favorable efficacy and safety results. Plausible
mechanisms for the minimization of side effects include
excluding up to 30% due to comorbidities [24].
These considerations justify the need for post market-
ing surveillance of adverse effects of new products. We
believe that pharmacokinetic studies are necessary to
investigate the levels of pravastatin in patients on COBI
and fenofibrate with and without other comorbidities.
Meanwhile, we encourage caution in the concomitant
use of EVG/COBI/FTC/TDF and pravastatin/fenofi-
brate. The case serves as an important reminder to use
eGFR rather than serum creatinine when choosing new
medications. If potentially nephrotoxic combinations
are started in patients with borderline eGFRs, it may be
prudent to check the eGFR more frequently than usual.
In patients with reduced eGFRs, potentially nephro-
toxic combinations should be avoided wherever pos-
sible. If there are no alternatives then patients should
be closely monitored and advised to report myalgia as
promptly as possible.
Fig. 1 Possible pathophysiological mechanisms leading to rhabdomyolysis and acute kidney injury in this case. 1B1 and 1B3 organic anion
transporters 1B1 and 1B3, 3A4 cytochrome P450 3A4, BCRP breast cancer resistance protein, GIT gastrointestinal tract, PGP P-glycoprotein,
PTC proximal tubular cell, X inhibited by cobicistat
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Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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